📰 Compass Pathways News
Page 28 - Compass Pathways News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Compass Pathways. Real-time updates on events, politics, business and more.
April 13, 2022
/PRNewswire/ -- Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults each year, and despite the abundance...
April 13, 2022
City investors are confident that psychedelics will be a vital tool in fighting depression and mental trauma
April 13, 2022
Wall Street analysts expect COMPASS Pathways plc (NASDAQ:CMPS – Get Rating) to announce earnings of ($0.68) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for COMPASS Pathways’ earnings, with the highest EPS estimate coming in at ($0.65) and the lowest estimate coming in at ($0.73). COMPASS Pathways […]
April 13, 2022
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, April 13, 2022 /PRNewswire/ -- Anxiety disorders are the most common mental illness in the US, affecting approximately
April 12, 2022
New research from Imperial College London purporting a breakthrough in treating depression using the active ingredient found in magic mushrooms grabbed...
April 7, 2022
Shares of COMPASS Pathways plc (NASDAQ:CMPS – Get Rating) gapped up prior to trading on Tuesday . The stock had previously closed at $13.37, but opened at $14.48. COMPASS Pathways shares last traded at $14.18, with a volume of 362 shares. CMPS has been the topic of a number of analyst reports. Zacks Investment Research […]
April 3, 2022
COMPASS Pathways plc (NASDAQ:CMPS – Get Rating) insider Ekaterina Malievskaia sold 6,372 shares of the business’s stock in a transaction dated Tuesday, March 29th. The shares were sold at an average price of $12.48, for a total transaction of $79,522.56. The sale was disclosed in a document filed with the SEC, which is available through […]
March 30, 2022
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, March 30, 2022 /PRNewswire/ -- Depression and anxiety affect millions around the world and the venom of a toad is the
March 30, 2022
- Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive
March 30, 2022
/PRNewswire/ -- Depression and anxiety affect millions around the world and the venom of a toad is the latest psychedelic compound being used as an alternative...